Assessment of drug–drug interaction of dapagliflozin with LCZ696 based on an LC–MS/MS method
Biomedical Chromatography · 2024
DOI: 10.1002/bmc.5924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2024. Verfasst von Lingmei Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Aminobutyrates, Benzhydryl Compounds, Biphenyl Compounds, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The co‐administration of dapagliflozin (DPF) and sacubitril/valsartan (LCZ696) has emerged as a promising therapeutic approach for managing heart failure. Given that DPF and LCZ696 are substrates for P‐glycoprotein, there is a plausible potential for drug–drug interactions when administered concomitantly. To investigate the pharmacokinetic changes when these drugs are co‐administered, we have established and validated a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method capable of simultaneously detecting DPF, LBQ657 (the active metabolite of sacubitril) and valsartan in rat plasma. This method has demonstrated selectivity, sensitivity, and accuracy. Drug–drug interactions were examined by the LC–MS/MS method. The mechanisms were investigated using everted intestinal sac models and Caco‐2 cells. The results showed that DPF significantly increased the area under the curve (AUC (0– t ) ) (3,563.3 ± 651.7 vs. 7,146.5 ± 1,714.9 h μg/L) of LBQ657 (the active metabolite of sacubitril) and the AUC (0– t ) (24,022.4 ± 6,774.3 vs. 55,728.3 ± 32,446.3 h μg/L) of valsartan after oral co‐administration. Dapagliflozin significantly increased the amount of LBQ657 and valsartan in intestinal sacs by 1‐ and 1.25‐fold at 2.25 h. Caco‐2 cell uptake studies confirmed that P‐glycoprotein is the transporter involved in this interaction. This finding enhances the understanding of drug–drug interactions in the treatment of heart failure and provides a guidence for clinical therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
- Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China.
- Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, People's Republic of China.
ORCID-Profile: Lingmei Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, L., Liang, B., Teng, Y., Zhang, C., Zhang, Y., Zhang, Z., Zhang, A., Dong, S., & Fan, H. (2024). Assessment of drug–drug interaction of dapagliflozin with LCZ696 based on an LC–MS/MS method. Biomedical Chromatography. https://doi.org/10.1002/bmc.5924
Vancouver
Wang L, Liang B, Teng Y, Zhang C, Zhang Y, Zhang Z, et al. Assessment of drug–drug interaction of dapagliflozin with LCZ696 based on an LC–MS/MS method. Biomedical Chromatography. 2024. doi:10.1002/bmc.5924
BibTeX
@article{Wang2024,
author = {Wang, Lingmei and Liang, Bohan and Teng, Yunhua and Zhang, Chenchen and Zhang, Yufeng and Zhang, Zhidan and Zhang, Aijie and Dong, Shiqi and Fan, Huirong},
title = {Assessment of drug–drug interaction of dapagliflozin with LCZ696 based on an LC–MS/MS method},
journal = {Biomedical Chromatography},
year = {2024},
doi = {10.1002/bmc.5924}
}
EUVIMED